Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dustin Portela

Dermatology Boise, ID Doctor of Osteopathy

NPI 1588002547 CMS profile 1389125

6051 N Eagle Rd, Boise, ID 83713

Open in the dashboard

General payments

$164,143

522 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$661 paid to institutions, not to them · program year 2022

Through program year 2025, Dustin Portela of Boise, ID is reported in the CMS Open Payments database as having received $164,143 across 522 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $661 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,272 82
2024 General $41,061 86
2023 General $45,582 75
2022 General $14,739 81
2021 General $31,265 94
2020 General $8,557 42
2019 General $21,666 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dustin Portela
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Dustin Portela were reported at $1,272. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Dustin Portela Dermatology median Middle half National median
2019 $21,666 $454 $129–$1,240 $163
2020 $8,557 $235 $81–$756 $114
2021 $31,265 $377 $108–$1,108 $132
2022 $14,739 $514 $143–$1,391 $149
2023 $45,582 $607 $159–$1,674 $160
2024 $41,061 $751 $204–$1,903 $164
2025 $1,272 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dermavant Sciences, Inc. $58,697 21 payments
  2. AbbVie, Inc. $23,375 144 payments
  3. Lilly USA, LLC $20,434 26 payments
  4. Amgen Inc. $18,681 32 payments
  5. Genzyme Corporation $13,195 42 payments
  6. Celgene Corporation $10,462 13 payments
  7. Sun Pharmaceutical Industries Inc. $9,987 19 payments
  8. Novartis Pharmaceuticals Corporation $4,366 45 payments
  9. Pfizer Inc. $1,534 11 payments
  10. Galderma Laboratories, L.P. $657 40 payments
  11. Other $2,755 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $88,668 10 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,190 30 payments
  3. Food and Beverage $9,109 452 payments
  4. Travel and Lodging $7,887 25 payments
  5. Education $289 5 payments
Products named General payments · program years 2019–2025
  1. VTAMA $29,477 23 payments
  2. TAPINAROF $29,250 1 payment
  3. TALTZ $19,823 24 payments
  4. RINVOQ $14,105 21 payments
  5. DUPIXENT $13,320 46 payments
  6. Otezla Inflammation $11,758 25 payments
  7. Otezla Dermatology $10,443 9 payments
  8. Odomzo $9,615 3 payments
  9. SKYRIZI $6,981 83 payments
  10. Otezla Inflammation $6,923 7 payments
  11. Other $13,014 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

677

Median for Dermatology: 534

Drug cost

$658,917

Median for Dermatology: $67,151

Branded share of claims

16.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 16 $321,636
Humira(Cf) Pen Adalimumab Brand 16 $166,527
Dupixent Pen Dupilumab Brand 37 $139,948
Cromolyn Sodium Generic 17 $10,017
Clobetasol Propionate Generic 91 $5,982
Fluorouracil Generic 37 $3,785
Tacrolimus Generic 19 $3,783
Fluocinonide Generic 26 $1,361
Triamcinolone Acetonide Generic 86 $1,163
Doxycycline Hyclate Generic 42 $996

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$84,613

Medicare's payments for the services billed

Medicare patients

417

Average age 73

Services billed

2,034

192 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 43%
Diabetes 21%
Ischemic heart disease 16%
Atrial fibrillation 16%
Chronic kidney disease 16%
Depression 16%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TAPINAROF
  • Dermavant Sciences, Inc. $29,250
$29,250 — —
Odomzo
  • Sun Pharmaceutical Industries Inc. $9,579
$9,579 — —
SKYRIZI
  • AbbVie, Inc. $849
$849 16 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $288
$288 — —
DUPIXENT
  • GENZYME CORPORATION $138
  • Regeneron Healthcare Solutions, Inc. $35
$173 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

522 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record